Abstract #4694

Early evaluation of subclinical cardiotoxicity in HER2-positive breast cancer patients with low-moderate cardiovascular risk using MRI

Sainan Cheng¹, Jianwei Wang¹, Yawen Wang¹, Linlin Qi¹, Fenglan Li¹, Jianing Liu¹, Jiaqi Chen¹, Yang Fan², and Lizhi Xie²

¹Department of Diagnostic Radiology, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²MR Research China, GE Healthcare, Beijing, China

Synopsis

Keywords: Heart, Cardiovascular, cardiotoxicityThis study explored the early cardiac changes in HER2-positive patients treated with HER2-targeted or anthracycline therapy through cardiac MRI. The results showed frequent signs of subclinical cardiotoxicity after short-term anti-cancer therapy, despite with low-moderate cardiovascular risk. T1 mapping showed the capability for early detection of pathological myocardial changes before cardiac contractile dysfunction. In HER2-positive breast cancer patients, cardiotoxicity surveillance is important and should be carefully done even with low-moderate cardiovascular risk, especially for those received anthracycline-based therapy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.